相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy
Itay Lotan et al.
CURRENT NEUROPHARMACOLOGY (2021)
Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases
Pierre Durozard et al.
ANNALS OF NEUROLOGY (2020)
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Gustavo Luna et al.
JAMA NEUROLOGY (2020)
Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancy
Kathleen C. Munger et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions
Kristen M. Krysko et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
Finn Sellebjerg et al.
CNS DRUGS (2020)
Emerging therapeutic targets for neuromyelitis optica spectrum disorder
Lukmanee Tradtrantip et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations
Yang Mao-Draayer et al.
NATURE REVIEWS NEUROLOGY (2020)
Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study
Yoshiki Takai et al.
BRAIN (2020)
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
James E. Frampton
DRUGS (2020)
Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options
Mattia Rosso et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2020)
2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases
Lisa R. Sammaritano et al.
ARTHRITIS & RHEUMATOLOGY (2020)
From Normal Flora to Brain Abscesses: A Review of Streptococcus intermedius
Elio Issa et al.
FRONTIERS IN MICROBIOLOGY (2020)
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Anthony Traboulsee et al.
LANCET NEUROLOGY (2020)
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial
Chao Zhang et al.
LANCET NEUROLOGY (2020)
Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders
Itay Lotan et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Translating IL-6 biology into effective treatments
Ernest H. Choy et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
Rituximab, MS, and pregnancy
Jessica B. Smith et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases
Simone Mader et al.
CURRENT OPINION IN NEUROLOGY (2020)
Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules
Benjamin P. Trewin et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Interleukin-6: A Masterplayer in the Cytokine Network
Peter Uciechowski et al.
ONCOLOGY (2020)
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
Mark A. Agius et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
Mark A. Agius et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Treating neuromyelitis optica with azathioprine: 20-year clinical practice
Denis Bernardi Bichuetti et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Treating neuromyelitis optica with azathioprine: 20-year clinical practice
Denis Bernardi Bichuetti et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Eculizumab in pregnancy: a narrative overview
Laura Sarno et al.
JOURNAL OF NEPHROLOGY (2019)
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis
Srikanth Muppidi et al.
MUSCLE & NERVE (2019)
Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica
John Soltys et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Placental passage of eculizumab and complement blockade in a newborn
Caroline Duineveld et al.
KIDNEY INTERNATIONAL (2019)
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
S. J. Pittock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Placental transfer of tocilizumab in a patient with rheumatoid arthritis
Yoshifumi Tada et al.
RHEUMATOLOGY (2019)
Targeting the complement system in bacterial meningitis
Diederik L. H. Koelman et al.
BRAIN (2019)
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Bruce A. C. Cree et al.
LANCET (2019)
A new era for neuromyelitis optica spectrum disorder
Elizabeth Silbermann et al.
LANCET (2019)
Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder
Santiago Pardo et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
B cells in autoimmune and neurodegenerative central nervous system diseases
Joseph J. Sabatino et al.
NATURE REVIEWS NEUROSCIENCE (2019)
Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica
Richard K. Burt et al.
NEUROLOGY (2019)
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
Takashi Yamamura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden
Kathrine Lederballe Gron et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis
Wenjuan Huang et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Blockade of IL-6 signaling in neuromyelitis optica
Manabu Araki
NEUROCHEMISTRY INTERNATIONAL (2019)
Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD)
Yara Dadalti Fragoso et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Serum sickness following rituximab therapy in multiple sclerosis
Trygve Holmoy et al.
NEUROLOGY-CLINICAL PRACTICE (2019)
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
Nicky Dunn et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
Nicky Dunn et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Interleukin-6: designing specific therapeutics for a complex cytokine
Christoph Garbers et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders
J. Ciron et al.
REVUE NEUROLOGIQUE (2018)
Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders
A. Sebastian Lopez-Chiriboga et al.
JAMA NEUROLOGY (2018)
Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder
Maureen A. Mealy et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Obstetric outcomes in a Mexican cohort of patients with AQP4-antibody-seropositive neuromyelitis optica
Guillermo Delgado-Garcia et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies
Nadja Borisow et al.
EPMA JOURNAL (2018)
New insights and long-term safety of tocilizumab in rheumatoid arthritis
Graeme Jones et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2018)
Rituximab before and during pregnancy A systematic review, and a case series in MS and NMOSD
Gitanjali Das et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)
Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
Sylvia Heink et al.
NATURE IMMUNOLOGY (2017)
Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
Jan-Patrick Stellmann et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management
Eslam Shosha et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
High risk of postpartum relapses in neuromyelitis optica spectrum disorder
Eric C. Klawiter et al.
NEUROLOGY (2017)
Low level of Rituximab in human breast milk in a patient treated during lactation
Yngvill Bragnes et al.
RHEUMATOLOGY (2017)
Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management
Eslam Shosha et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Neuromyelitis Optica: Deciphering a Complex Immune Mediated Astrocytopathy
Jeffrey L. Bennett et al.
JOURNAL OF NEURO-OPHTHALMOLOGY (2017)
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro
Yukio Takeshita et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab
Ferras Alashkar et al.
ANNALS OF HEMATOLOGY (2017)
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series
Laura Azzopardi et al.
JOURNAL OF NEUROLOGY (2016)
Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints
In Hye Jeong et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients
M. Radaelli et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder
Matthew M. Nour et al.
NEUROLOGY (2016)
Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints
In Hye Jeong et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients
M. Radaelli et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare
Huifeng Yun et al.
ARTHRITIS & RHEUMATOLOGY (2016)
The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China
Hongxi Chen et al.
CLINICAL NEUROPHARMACOLOGY (2016)
Th17 cells in neuromyelitis optica spectrum disorder: a review
Jie Lin et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2016)
Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway
Janus Asbjorn Schatz-Jakobsen et al.
JOURNAL OF IMMUNOLOGY (2016)
Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study
Yan Xu et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2016)
Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan
Ken Nakajima et al.
MODERN RHEUMATOLOGY (2016)
Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy
Jonatan Salzer et al.
NEUROLOGY (2016)
Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data
Maria Hoeltzenbein et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies
Ding Chen et al.
JOURNAL OF CLINICAL MEDICINE (2016)
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder
Margherita Nosadini et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
Elena Schiopu et al.
ARTHRITIS RESEARCH & THERAPY (2016)
The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model
Christian Geis et al.
EXPERIMENTAL NEUROLOGY (2015)
Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn
Randi Fykse Hallstensen et al.
IMMUNOBIOLOGY (2015)
Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant
Patrick Aouad et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability
Helene Zephir et al.
JOURNAL OF NEUROLOGY (2015)
Analysis of the treatment of neuromyelitis optica
Jose Torres et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk et al.
NEUROLOGY (2015)
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria
Richard J. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder
Marius Ringelstein et al.
JAMA NEUROLOGY (2015)
Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party
Raffaella Greco et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Update on the Teratogenicity of Maternal Mycophenolate Mofetil
Lisa A. Coscia et al.
JOURNAL OF PEDIATRIC GENETICS (2015)
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Ramnath Santosh Ramanathan et al.
BMC NEUROLOGY (2014)
Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease
Bindia Jharap et al.
GUT (2014)
Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab
Joanna Kitley et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK
Liene Elsone et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
PREGNANCY OUTCOMES IN A WOMAN WITH NEUROMYELITIS OPTICA
Nasrin Asgari et al.
NEUROLOGY (2014)
Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study
Manabu Araki et al.
NEUROLOGY (2014)
Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica Multicenter Study of Treatment Efficacy
Maureen A. Mealy et al.
JAMA NEUROLOGY (2014)
The effect of rituximab on vaccine responses in patients with immune thrombocytopenia
Ishac Nazi et al.
BLOOD (2013)
Efficacy of Intravenous Cyclophosphamide Therapy for Neuromyelitis Optica Spectrum Disorder
Hiroaki Yaguchi et al.
INTERNAL MEDICINE (2013)
Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica
Takashi Kageyama et al.
JOURNAL OF NEUROLOGY (2013)
Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
Joanna Kitley et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study
Sean J. Pittock et al.
LANCET NEUROLOGY (2013)
Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica
Chun-Sheng Yang et al.
NEUROLOGY (2013)
Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica Implication for Cellular Immune Responses
Bernd C. Kieseier et al.
JAMA NEUROLOGY (2013)
Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy
Ilya Ayzenberg et al.
JAMA NEUROLOGY (2013)
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder
Su-Hyun Kim et al.
JAMA NEUROLOGY (2013)
Aquaporin 4-Specific T Cells in Neuromyelitis Optica Exhibit a Th17 Bias and Recognize Clostridium ABC Transporter
Michel Varrin-Doyer et al.
ANNALS OF NEUROLOGY (2012)
Lack of Response to Pulse Cyclophosphamide in Neuromyelitis Optica: Evaluation of 7 Patients
Denis B. Bichuetti et al.
ARCHIVES OF NEUROLOGY (2012)
Teratogen update: Methotrexate
Sara C. Hyoun et al.
BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY (2012)
IgG Placental Transfer in Healthy and Pathological Pregnancies
Patricia Palmeira et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
Sven Jarius et al.
JOURNAL OF NEUROINFLAMMATION (2012)
Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?
Su-Hyun Kim et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Influence of pregnancy on neuromyelitis optica spectrum disorder
W. Kim et al.
NEUROLOGY (2012)
Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms
Hua Zhang et al.
ANNALS OF NEUROLOGY (2011)
Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years
Su-Hyun Kim et al.
ARCHIVES OF NEUROLOGY (2011)
Efficacy and Safety of Mitoxantrone in Patients With Highly Relapsing Neuromyelitis Optica
Su-Hyun Kim et al.
ARCHIVES OF NEUROLOGY (2011)
Impact of rituximab on relapse rate and disability in neuromyelitis optica
Gurdesh S. Bedi et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Azathioprine Tolerability, efficacy, and predictors of benefit in neuromyelitis optica
C. Costanzi et al.
NEUROLOGY (2011)
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
H. L. Pellkofer et al.
NEUROLOGY (2011)
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
Norio Chihara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
Laura Campbell et al.
RHEUMATOLOGY (2011)
Relapsing Neuromyelitis Optica: demographic and clinical features in Iranian patients
M. A. Sahraian et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
gp130 at the nexus of inflammation, autoimmunity, and cancer
J. S. Silver et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2010)
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Tomoyuki Igawa et al.
NATURE BIOTECHNOLOGY (2010)
Early Pregnancy Azathioprine Use and Pregnancy Outcomes
Brian J. Cleary et al.
BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY (2009)
Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis
Akiyuki Uzawa et al.
JOURNAL OF NEUROLOGY (2009)
Azathioprine treatment during lactation
L. A. Christensen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Treatment of Neuromyelitis Optica With Rituximab Retrospective Analysis of 25 Patients
Anu Jacob et al.
ARCHIVES OF NEUROLOGY (2008)
Pregnancy outcome of women exposed to azathioprine during pregnancy
Lee Hilary Goldstein et al.
BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY (2007)
Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis
S. Watanabe et al.
MULTIPLE SCLEROSIS (2007)
Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response
Ferdinand Breedveld et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Azathioprine and breastfeeding - is it safe?
A. Sau et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2007)
The spectrum of neuromyelitis optica
Dean M. Wingerchuk et al.
LANCET NEUROLOGY (2007)
Study of mitoxantrone for the treatment of recurrent neuromyelitis Optica (Devic disease)
Bianca Weinstock-Guttman et al.
ARCHIVES OF NEUROLOGY (2006)
Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment
F. Falcini et al.
RHEUMATOLOGY (2006)
Azathioprine use during pregnancy: Unexpected intrauterine exposure to metabolites
NKH de Boer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
An open label study of the effects of rituximab in neuromyelitis optica
BAC Cree et al.
NEUROLOGY (2005)
The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: A retrospective cohort study
A Francella et al.
GASTROENTEROLOGY (2003)
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica
CF Lucchinetti et al.
BRAIN (2002)
分享论文
